A detailed history of Rhs Financial, LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Rhs Financial, LLC holds 12,326 shares of EXEL stock, worth $513,377. This represents 0.27% of its overall portfolio holdings.

Number of Shares
12,326
Previous 12,297 0.24%
Holding current value
$513,377
Previous $542,000 6.09%
% of portfolio
0.27%
Previous 0.32%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Oct 22, 2025

BUY
$36.22 - $46.25 $1,050 - $1,341
29 Added 0.24%
12,326 $509,000
Q2 2025

Jul 25, 2025

BUY
$34.13 - $46.26 $17,713 - $24,008
519 Added 4.41%
12,297 $542,000
Q1 2025

Apr 17, 2025

BUY
$32.38 - $39.16 $381,371 - $461,226
11,778 New
11,778 $434,000

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $13.4B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Rhs Financial, LLC Portfolio

Follow Rhs Financial, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhs Financial, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rhs Financial, LLC with notifications on news.